Barack Obama and the Monsanto betrayal By Jon

New Post Public Reply Private Reply Replies (0) Message Board
SaltyMutt
Barack Obama and the Monsanto betrayal

By Jon Rappoport
May 12, 2014

Under the selective radar of mainstream media, Barack Obama has been carving out a whole new level of support for Monsanto and other destructive biotech giants.

From Scott Creighton, “Obama Pitches India Model of GM Genocide to Africa”:

“At the G8 Summit held two weeks ago at Camp David, President Obama met with private industry and African heads of state to launch the New Alliance for Food Security and Nutrition, a euphemism for monocultured, genetically modified crops and toxic agrochemicals aimed at making poor farmers debt slaves to corporations, while destroying the ecosphere for profit.

“But African civil society wants no part of this latest Monsanto aligned ‘public private partnership.’ Whatever will the progressives do now that their flawless hero has teamed up with their most hated nemesis [Monsanto] to exploit an entire continent like they did to India not that long ago?…

“With a commitment of $3 billion, Obama plans to ‘partner up’ with mega-multinationals like Monsanto, Diageo, Dupont, Cargill, Vodafone, Walmart, Pepsico, Prudential, Syngenta International, and Swiss Re because, as one USAID representative says ‘There are things that only companies can do, like building silos for storage and developing seeds and fertilizers.’

“Of course, that’s an outrageous lie. Private citizens have been building their own silos for centuries. But it’s true that only the biowreck engineers will foist patented seeds and toxic chemicals on Africa.”

Under the guise of replacing the “donor-recipient model” of charity with “smart business development that’s a win-win for everybody,” a new level of corporate-government colonialism is aimed at the continent of Africa. The new and improved strategy means bigger profits for the few and greater suffering and displacement for the many.

Support self-sufficiency for the small farmer? Expand the number of small farms growing nutritious and non-toxic food? Never heard of it. Not on the agenda—except in false propaganda statements and promises.

No, instead, the idea is putting small farmers into debt to Monsanto for GMO seeds and highly toxic herbicides, so they can grow (until they go bankrupt) noxious GMO food crops. Small farms will eventually be snapped up by big ag corporations.

Obama? A warrior against corporations on behalf of the people? It’s long past the time for ripping that false mask away.

During his 2008 campaign for president, Barack Obama transmitted signals that he understood the GMO issue. Several key anti-GMO activists were impressed. They thought Obama, once in the White House, would listen to their concerns and act on them.

These activists weren’t just reading tea leaves. On the campaign trail, Obama said: “Let folks know when their food is genetically modified, because Americans have a right to know what they’re buying.” (bolded for emphasis)

Making the distinction between GMO and non-GMO was certainly an indication that Obama, unlike the FDA and USDA, saw there was an important line to draw in the sand.

Beyond that, Obama was promising a new era of transparency in government. He was adamant in assuring that, if elected, his administration wouldn’t do business in “the old way.” He would be “responsive to people’s needs.”

Then came the reality.

After the election, people who had been working to label GMO food and warn the public of its huge dangers were shocked to the core. They saw Obama had been pulling a bait and switch.

After the 2008 election, Obama filled key posts with Monsanto people, in federal agencies that wield tremendous force in food issues, the USDA and the FDA:

* At the USDA, as the director of the National Institute of Food and Agriculture, Roger Beachy, former director of the Monsanto Danforth Center.

* As deputy commissioner of the FDA, the new food-safety-issues czar, the infamous Michael Taylor, former vice-president for public policy for Monsanto. Taylor had been instrumental in getting approval for Monsanto’s genetically engineered bovine growth hormone.

* As commissioner of the USDA, Iowa governor, Tom Vilsack. Vilsack had set up a national group, the Governors’ Biotechnology Partnership, and had been given a Governor of the Year Award by the Biotechnology Industry Organization, whose members include Monsanto.

* As the new Agriculture Trade Representative, who would push GMOs for export, Islam Siddiqui, a former Monsanto lobbyist.

* As the new counsel for the USDA, Ramona Romero, who had been corporate counsel for another biotech giant, DuPont.

* As the new head of the USAID, Rajiv Shah, who had previously worked in key positions for the Bill and Melinda Gates Foundation, a major funder of GMO agriculture research.

* We should also remember that Obama’s secretary of state, Hillary Clinton, once worked for the Rose law firm. That firm was counsel to Monsanto.

* Obama nominated Elena Kagan to the US Supreme Court. Kagan, as federal solicitor general, had previously argued for Monsanto in the Monsanto v. Geertson seed case before the Supreme Court.

The deck was stacked. Obama hadn’t simply made honest mistakes. Obama hadn’t just failed to exercise proper oversight in selecting appointees. He wasn’t just experiencing a failure of short-term memory. He was staking out territory on behalf of Monsanto and other GMO corporate giants. (my bolding for emphasis)

And now let us look at what key Obama appointees have wrought for their true bosses. Let’s see what GMO crops have walked through the open door of the Obama presidency.

Monsanto GMO alfalfa.

Monsanto GMO sugar beets.

Monsanto GMO Bt soybean.

Coming soon: Monsanto’s GMO sweet corn.

Syngenta GMO corn for ethanol.

Syngenta GMO stacked corn.

Pioneer GMO soybean.

Syngenta GMO Bt cotton.

Bayer GMO cotton.

ATryn, an anti-clotting agent from the milk of transgenic goats.

A GMO papaya strain.

And perhaps, soon, genetically engineered salmon and apples.

This is an extraordinary parade. It, in fact, makes Barack Obama the most GMO-dedicated politician in America. (my bolding)

You don’t attain that position through errors or oversights. Obama was, all along, a stealth operative on behalf of Monsanto, biotech, GMOs, and corporate control of the future of agriculture.

From this perspective, Michelle Obama’s campaign for gardens and clean, organic, nutritious food is nothing more than a diversion, a cover story floated to obscure what her husband has actually been doing.

Nor is it coincidental that two of the Obama’s biggest supporters, Bill Gates and George Soros, purchased 900,000 and 500,000 shares of Monsanto, respectively, in 2010.

We are talking about a president who presented himself, and was believed by many to be, an extraordinary departure from politics as usual.

Not only was that a wrong assessment, Obama was lying all along. He was, and he still is, Monsanto’s man in Washington.

To those people who fight for GMO labeling and the outlawing of GMO crops, and against the decimation of the food supply and the destruction of human health, but still believe Obama is a beacon in bleak times:

Wake up.

Sources include:

http://redgreenandblue.org/2012/02/02/monsant...nt-part-2/

http://redgreenandblue.org/2011/02/09/monsant...overnment/

http://www.motherjones.com/tom-philpott/2011/...fied-foods

http://fooddemocracynow.org/blog/2011/feb/15/...-no-monsa/

http://www.foodandwaterwatch.org/food/genetic...red-foods/

http://news.yahoo.com/not-altruistic-truth-be...00462.html

Jon Rappoport

http://jonrappoport.wordpress.com/2014/05/07/...-betrayal/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 209

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 578

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 222

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 742

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 274

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 140

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 200

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading

Top 5 Most Recently Viewed Articles

Marina Genova Joins SEA Index to Promote Sustainable Yachting

Updated Category News Views 173

Marina Genova Enters SEA Index as an Institutional Member Recently, the Superyacht Eco Association – SEA Index welcomed Marina Genova, a prominent destination for yachting in the Mediterranean, as an Institutional Member. This collaboration signifies a crucial step in the yachting community's commitment to integrating environmental sustainability into its operations....

Continue Reading
Warren Buffett’s Top 2025 Stock Picks You Need to Know

Updated Category News Views 2610

Warren Buffett’s Strategic Stock Investments for 2025 Warren Buffett, the Oracle of Omaha, is known for his keen investment strategies and ability to recognize value in both good and bad market conditions. In the current volatile landscape, his portfolio continues to evolve, with some old favorites and new bets that show his forward-thinking approach. As we look ahead...

Continue Reading
Graves' Ophthalmopathy Market Surges with New Therapies

Updated Category News Views 50

Unexpected Growth in Graves' Ophthalmopathy Market Over the next decade, we're seeing the Graves' ophthalmopathy market gearing up for some serious growth, clocking in at a hefty compound annual growth rate of 9%. A good chunk of this is thanks to Viridian's newest player, LUMVOA, getting the green light, sending competitors scrambling and pushing innovation into...

Continue Reading
Tris Pharma Launches ONYDA XR: A New ADHD Liquid Solution

Updated Category News Views 210

So back in 2024, Tris Pharma rolled out ONYDA™ XR—this liquid medication aimed at tackling ADHD in kids six and older. It was billed as a game changer, especially since the FDA gave it the green light. The desks were buzzing about this first-of-its-kind non-stimulant therapy, positioning it like a golden ticket for parents tired of conventional stimulants that might...

Continue Reading
JPMorgan Updates Price Target for W. P. Carey to $70

Updated Category News Views 242

JPMorgan Boosts W. P. Carey's Price Target Recently, JPMorgan has refreshed its price target for W. P. Carey & Co. (NYSE: WPC), raising it from $68.00 to $70.00, while retaining an Overweight rating on the stock. This adjustment comes ahead of the company’s third-quarter earnings announcement, indicating the firm's confidence in W. P. Carey’s future potential....

Continue Reading